IL162079A0 - 3,4-Disubstituted, 3,5-disubstituted and substituted and 3,4,5-substituted piperidines and piperazines - Google Patents

3,4-Disubstituted, 3,5-disubstituted and substituted and 3,4,5-substituted piperidines and piperazines

Info

Publication number
IL162079A0
IL162079A0 IL16207902A IL16207902A IL162079A0 IL 162079 A0 IL162079 A0 IL 162079A0 IL 16207902 A IL16207902 A IL 16207902A IL 16207902 A IL16207902 A IL 16207902A IL 162079 A0 IL162079 A0 IL 162079A0
Authority
IL
Israel
Prior art keywords
disubstituted
substituted
piperazines
piperidines
substituted piperidines
Prior art date
Application number
IL16207902A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL162079A0 publication Critical patent/IL162079A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16207902A 2001-11-19 2002-11-19 3,4-Disubstituted, 3,5-disubstituted and substituted and 3,4,5-substituted piperidines and piperazines IL162079A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33270801P 2001-11-19 2001-11-19
US38316702P 2002-05-24 2002-05-24
PCT/US2002/037037 WO2003043987A2 (en) 2001-11-19 2002-11-19 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
IL162079A0 true IL162079A0 (en) 2005-11-20

Family

ID=26988352

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16207902A IL162079A0 (en) 2001-11-19 2002-11-19 3,4-Disubstituted, 3,5-disubstituted and substituted and 3,4,5-substituted piperidines and piperazines

Country Status (21)

Country Link
US (1) US7338965B2 (ru)
EP (1) EP1448200A2 (ru)
JP (1) JP2005514362A (ru)
KR (1) KR20050044533A (ru)
AP (1) AP2004003052A0 (ru)
AU (1) AU2002360403A1 (ru)
BR (1) BR0214295A (ru)
CA (1) CA2467749A1 (ru)
CO (1) CO5580743A2 (ru)
EA (1) EA200400699A1 (ru)
GE (1) GEP20074045B (ru)
HR (1) HRP20040550A2 (ru)
IL (1) IL162079A0 (ru)
IS (1) IS7271A (ru)
MX (1) MXPA04004772A (ru)
NO (1) NO20042580L (ru)
NZ (1) NZ533158A (ru)
OA (1) OA12812A (ru)
RS (1) RS54204A (ru)
TN (1) TNSN04088A1 (ru)
WO (1) WO2003043987A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
JP5564249B2 (ja) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
KR100679869B1 (ko) * 2006-10-27 2007-02-07 한국기계연구원 Dpf시스템용 플라즈마 반응기와 이를 이용한 입자상물질의 저감 장치
AU2007297627A1 (en) * 2006-09-21 2008-03-27 Merck Sharp & Dohme Corp. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of Alzheimer's disease
KR100838645B1 (ko) * 2006-09-28 2008-06-16 한국화학연구원 베타-세크리테아제 활성을 억제하는 피페리딘 화합물
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
KR100894713B1 (ko) * 2007-10-08 2009-04-24 한국화학연구원 베타-세크리테아제의 활성을 저해하는 아릴피페라진이 치환된 피페리딘 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 신경퇴행성 질환의 예방 또는 치료용 조성물
BRPI0921805A2 (pt) 2008-11-03 2016-11-01 Alethia Biotherapeutics Inc anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CN106146664B (zh) 2011-03-31 2021-09-07 Adc治疗股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
SI2802351T1 (sl) 2012-01-09 2019-07-31 ADC Therapeutics SA, Biopole Sredstva za zdravljenje trojno negativnega raka dojke
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4248876A (en) 1977-01-08 1981-02-03 John Wyeth & Brother Ltd. Piperidine derivatives
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3640475A1 (de) * 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
GB8714789D0 (en) 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5510487A (en) 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
PT810209E (pt) 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
US5475138A (en) 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
TR199800409T1 (xx) * 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
AU749281B2 (en) 1997-02-04 2002-06-20 Regents Of The University Of California, The Nanomolar, non-peptide inhibitors of cathepsin D
AU9740998A (en) 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
DE69817214T2 (de) * 1997-11-05 2004-06-09 Neurosearch A/S Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
EP1097137A1 (en) * 1998-07-10 2001-05-09 AstraZeneca AB N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
US6274735B1 (en) * 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
JP2002526528A (ja) * 1998-10-07 2002-08-20 ジョージタウン ユニヴァーシティー 単量体およびニ量体の複素環、ならびにその治療的使用
GB9904786D0 (en) 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2002066469A2 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JP2004534017A (ja) * 2001-04-27 2004-11-11 バーテックス ファーマシューティカルズ インコーポレイテッド Baceのインヒビター

Also Published As

Publication number Publication date
EP1448200A2 (en) 2004-08-25
AU2002360403A1 (en) 2003-06-10
US20040034031A1 (en) 2004-02-19
HRP20040550A2 (en) 2006-11-30
WO2003043987A3 (en) 2003-07-10
NO20042580L (no) 2004-08-09
RS54204A (en) 2006-12-15
CA2467749A1 (en) 2003-05-30
EA200400699A1 (ru) 2004-12-30
KR20050044533A (ko) 2005-05-12
CO5580743A2 (es) 2005-11-30
GEP20074045B (en) 2007-02-26
MXPA04004772A (es) 2005-06-06
BR0214295A (pt) 2004-11-09
US7338965B2 (en) 2008-03-04
TNSN04088A1 (en) 2006-06-01
AP2004003052A0 (en) 2004-06-30
WO2003043987A2 (en) 2003-05-30
OA12812A (en) 2006-07-10
NZ533158A (en) 2006-09-29
JP2005514362A (ja) 2005-05-19
IS7271A (is) 2004-05-19

Similar Documents

Publication Publication Date Title
IL162079A0 (en) 3,4-Disubstituted, 3,5-disubstituted and substituted and 3,4,5-substituted piperidines and piperazines
AU3740101A (en) 2,4-disubstituted thiazolyl derivatives
MXPA03009000A (es) Compuestos benzo-fusionados 1,4-disustituidos.
DE60220778D1 (en) 3,4-disubstituierte cyclobuten-1,2-dione als cxc-chemokinrezeptorliganden
HK1068895A1 (en) Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
ZA99314B (en) 4-(2-Keto-1-Benzimidazolinyl)piperidine compounds as orl1-receptor agonists.
IL162377A0 (en) 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
NO20033165L (no) (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav
GB2361235B (en) 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides
IL150550A0 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
HK1039489A1 (en) New piperazine and piperidine compounds.
EE200100498A (et) 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
HK1055952A1 (en) Piperazine an piperidine compounds.
HK1077296A1 (en) 2,5-Disubstituted 3-mercaptopentanoic acid
AU2231502A (en) 1,4-disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers
WO2002046156A3 (en) 4,4-DISUBSTITUTED PIPERIDINES AND THEIR METHODS OF USE
TR199902839A3 (tr) Yeni 4-ikameli piperidinler.
IL154675A0 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
GB0113342D0 (en) Novel Heterocycles 1
AU1018801A (en) Use of 3,4-substituted piperidines
DK1315700T3 (da) Substituerede 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridiner
IL143024A0 (en) 2,4-disubstituted triazine derivatives
IL163648A0 (en) B-ä'(2S)-4-(3,4-difluorobenzyl)morpholin-2-ylmethylü-2-ä3-'(methylsulphonyl)aminophenylüacetamide asccr3 antagonist
GB0113343D0 (en) Novel Heterocycles 2